C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.51 AUD Market Closed
Market Cap: 167.8m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Cyclopharm Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cyclopharm Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyclopharm Ltd
ASX:CYC
Cash & Cash Equivalents
AU$27.6m
CAGR 3-Years
-5%
CAGR 5-Years
37%
CAGR 10-Years
35%
R
Respiri Ltd
ASX:RSH
Cash & Cash Equivalents
AU$762.9k
CAGR 3-Years
-54%
CAGR 5-Years
20%
CAGR 10-Years
-21%
ImpediMed Ltd
ASX:IPD
Cash & Cash Equivalents
AU$24.6m
CAGR 3-Years
8%
CAGR 5-Years
17%
CAGR 10-Years
9%
Cochlear Ltd
ASX:COH
Cash & Cash Equivalents
AU$513.6m
CAGR 3-Years
-6%
CAGR 5-Years
46%
CAGR 10-Years
25%
Optiscan Imaging Ltd
ASX:OIL
Cash & Cash Equivalents
AU$6.1m
CAGR 3-Years
-10%
CAGR 5-Years
28%
CAGR 10-Years
56%
EMvision Medical Devices Ltd
ASX:EMV
Cash & Cash Equivalents
AU$18.6m
CAGR 3-Years
24%
CAGR 5-Years
34%
CAGR 10-Years
N/A
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
167.8m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.04 AUD
Undervaluation 26%
Intrinsic Value
Price
C

See Also

What is Cyclopharm Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
27.6m AUD

Based on the financial report for Jun 30, 2024, Cyclopharm Ltd's Cash & Cash Equivalents amounts to 27.6m AUD.

What is Cyclopharm Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
35%

Over the last year, the Cash & Cash Equivalents growth was 52%. The average annual Cash & Cash Equivalents growth rates for Cyclopharm Ltd have been -5% over the past three years , 37% over the past five years , and 35% over the past ten years .

Back to Top